Back to search

University of Ioannina

Μελέτη του ρόλου μορίων της κυτταρικής επιφανείας του συμπλέγματος διαφοροποίησης (CD) στην ανάπτυξη του καρκίνου και ρόλος της κανονικής σηματοδοτικής πορείας του NF-κΒ στην ρύθμιση των μορίων CD

Abstract

dc:description

Carcinogenesis is a multistep process, which at a cellular level involves the accumulation of genetic mutations in conjunction with epigenetic modifications, resulting in dominant alterations in gene expression and cellular physiology. Consequently, these changes lead to uncontrolled cell division and evasion of apoptosis. The development and progression of cancer, however, is a much more complex process involving also cells and other factors present in the tumor microenvironment, including the host's immune system. Among the cluster of differentiation cell surface molecules that are involved in carcinogenesis are tetraspanins. Tetraspanins are transmembrane proteins that span the cell membrane with 4 α-helices and regulate multiple biological processes through their ability to cluster and organize specific receptors and signaling proteins into micro-regions/-domains on the cell surface. These proteins combine with each other, as well as with a series of other transmembrane and cytoplasmic proteins to form membrane microdomains (tetraspanin enriched microdomains - TEMs). These protein complexes are also referred to in the literature as tetraspanin webs. By definition, a key feature of tetraspanins is to organize specific receptors and signaling proteins into membrane microdomains on the cell surface. Tetraspanins have received particular recognition, as their distinct mechanism of action allows them to have multiple and diverse functions within a single cell and/or between different cell types. Tetraspanins are involved normally in fundamental cellular processes such as cell proliferation, differentiation and migration. In the immune system, tetraspanins interact with prominent leukocyte receptors leading to their activation and the downstream signal transduction pathways. Among the biological processes tetraspanins are involved in, there is evidence that they are implicated in carcinogenesis, acting as tumor of metastasis suppressors or promoters, as well as regulating the immune response in the tumor microenvironment. However, due to the pleiotropic functions of tetraspanins, the precise molecular mechanisms contributing to carcinogenesis but also in the immune response are not fully understood. The tetraspanin family includes the surface molecules CD81 and CD82. CD82 tetraspanin is thought to act as a tumor suppressor, while CD81 tetraspanin has been thought to be a tumor promoter, however, given their pleiotropic functions, their role in colon cancer remains unknown. With the present proposal we aim to investigate the role of tetraspanins CD81 and CD82 in the development and progression of colon cancer. In the current study we examined, in patients with colon cancer by using immunohistochemistry, the expression of the tetraspanins CD81 and CD82 and the expression of the markers PD1 and PDL1 in tumor cells as well as in tumor infiltrating lymphocytes. We also examined the infiltration of the tumor microenvironment by CD3(+) and CD8(+) lymphocytes. For that purpose, fixed patient tissues in the form of tissue-microarrays (TMAs) were used. The patients' immunohistochemical data were correlated with their clinical and laboratory findings. We also estimated the overall survival and progression-free survival of the colon cancer patients according to their pathologic, clinical and laboratory characteristics. Our aim was to evaluate the role of each of these molecules/markers in colon cancer, acting either as suppressors or promoters of carcinogenesis, as well as to determine their prognostic and/or predictive value. Furthermore, we studied the role of tetraspanin CD81 in the progression (growth, tumor cell motility and tumorigenicity) of colon cancer in vitro, investigated possible mechanisms of action and examined whether the normal NF-κB signaling pathway is involved in the regulation of its expression CD81 in colon cancer cells. For this reason, we modified the expression of CD81 in DLD1, HCT116, CACO2 colon cancer cells. Using retroviral vectors, we were able to downregulate the expression of CD81 in DLD1, HCT116, CACO2 cells (using shRNA against CD81), and also upregulate CD81 expression in HCT116, CACO2 cells (using a retroviral vector carrying a of the CD81 gene).Results:•We observed that patients with a performance status (PS) 0, had a lower expression of CD81 by immunohistochemistry on cancer cells compares to patients with PS 1 or 2.•Patients with mismatch-repair (MMR) proficient tumors had a higher CD81 expression by immunohistochemistry on cancer cells than MMR-deficient patients •Non-metastatic patients were found to have a higher percentage of CD81(+)-lymphocytes infiltrating their tumors than metastatic patients.• We observed a negative correlation between the expression by immunohistochemistry of CD81 on tumor cells and tumor infiltrating CD3(+) and CD8(+) lymphocytes. •We found that CD82 expression on cancer cells by immunohistochemistry was less prominent in higher disease stages according to TNM staging, with metastatic patients displaying much lower levels of CD82 expression compared to non-metastatic patients. •We observed that patients with R1 or R2 resection had reduced expression of CD82 in tumor tissues compared to patients who had R0 resection. •Patients with elevated values of the tumor markers CEA and CA 19-9 displayed reduced CD82 expression on tumor cells by immunohistochemistry. •We observed that left-sided primary tumors displayed higher CD82 expression on cancer cells by immunohistochemistry, compared to right-sided primary tumors. •Metastatic patients, patients with a poor general health status (PS1 or 2) and patients with elevated CEA and CA 19-9 values, displayed a reduced percentage of CD82(+) tumor infiltrating lymphocytes. •The percentage of PD1(+) tumor cells was higher in non-metastatic patients compared to metastatic patients. •A higher percentage of PD1(+) tumor cells and PD1(+) lymphocytes was observed in patients with low CEA and CA 19-9 tumor marker values. •We observed a positive correlation between the expression of CD81 and CD82 on tumor cells and the expression of PD1 on tumor cells. •We observed a positive correlation between PD1(+)-lymphocytes and CD81(+)-lymphocytes, CD82(+)-lymphocytes, CD3(+)-lymphocytes, CD8(+)-lymphocytes. •The percentage of CD3(+) and CD8(+) tumor infiltrating lymphocytes was higher in non-metastatic patients compared to metastatic. •The percentage of CD3(+) and CD8(+) tumor infiltrating lymphocytes was higher in patients with a good performance status (PS0 vs PS1&2).•Infiltration by CD8(+)-lymphocytes was lower in patients with high CEA and Ca 19-9 values. •Infiltration by CD8(+) lymphocytes was higher in MMR-deficient patients. •Patients with a higher percentage of infiltrating CD81(+) lymphocytes demonstrated better overall survival (OS) and progression-free survival (PFS). •We observed that increased expression by immunohistochemistry of tetraspanin CD82 in tumor cells as well as increased percentage of infiltrating CD82(+) lymphocytes was associated with better overall and progression-free survival. •Patients with higher percentages of PD1(+) tumor cells or PD1(+) infiltrating tumor lymphocytes, had a lower risk of death (OS) and/or relapse (PFS).•Patients with higher percentages CD8(+) infiltrating tumor lymphocytes demonstrated improved overall and progression-free survival. •We confirmed the prognostic value of the already known clinical and pathological parameters, such as disease stage, complete surgical resection and values of CEA and CA 19-9 tumor markers. •We found that tetraspanin CD81 promotes in vitro the proliferation rate of human colon cancer cells DLD1, CACO2 and HCT116. •We found that tetraspanin CD81 in vitro increases the motility of human colon cancer cells DLD1, CACO2 and HCT116. •We found that tetraspanin CD81 in vitro promotes tumorigenesis in DLD1 colon cancer cells. •We found that tetraspanin CD81 in vitro promotes cell cycle progression by positively influencing the expression of the transcription factors E2F1 and CDC6.•We observed a possible interaction of the tetraspanin CD81 with the signaling pathways of NF-κB, which, however, needs further investigation. In conclusion, we found by immunohistochemistry that tetraspanin CD82 has a protective role in the development and progression of colon cancer, as its expression in cancer tissues was associated with favorable clinicopathological characteristics of patients and increased survival. Similarly, PD1 expression was also identified as a positive prognostic factor by immunohistochemistry. Additionally, we observed by immunohistochemistry that the tetraspanin CD81 probably functions by suppressing the immune response in the tumor microenvironment in colon cancer, since infiltration of CD3(+) and CD8(+) T-lymphocytes was less prominent in patients with high CD81 expression in tumor cells. Finally, we found that tetraspanin CD81 contributes in vitro to the growth and progression of colon cancer, by promoting cancer cells’ proliferation and motility, while also positively regulating cell cycle progression.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ntellas, Panagiotis
  • Ντέλλας, Παναγιώτης

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/53973

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ntellas, Panagiotis; Ντέλλας, Παναγιώτης. Μελέτη του ρόλου μορίων της κυτταρικής επιφανείας του συμπλέγματος διαφοροποίησης (CD) στην ανάπτυξη του καρκίνου και ρόλος της κανονικής σηματοδοτικής πορείας του NF-κΒ στην ρύθμιση των μορίων CD. University of Ioannina, 2022. http://hdl.handle.net/10442/hedi/53973